U.S., Nov. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07936292) titled 'Efficacy and Safety of Mirogabalin in Uremic Pruritus' on Nov. 07.
Brief Summary: This study aims to assess the efficacy and safety of mirogabalin in alleviating moderate-to-severe uremic pruritus in patients undergoing maintenance hemodialysis, and to establish the optimal dosing frequency by comparing continuous daily administration against intermittent post-dialysis administration.
Study Start Date: Dec., 2026
Study Type: INTERVENTIONAL
Condition:
Uremic Pruritus
Intervention:
DRUG: Mirogabalin (Intermittent)
Patients will receive mirogabalin 5 mg three times per week, administered immediately after each hemodialysis sessi...